Uncategorized
Eleven Biotherapeutics reports net income, revenue increases in third quarter
Eleven Biotherapeutics reported a net income of $19.5 million, or $0.95 per basic share and $0.91 per diluted share, in the third quarter compared with a net loss of $9.7 million, or $0.50 per basic and diluted share, in the same quarter of 2015, according to a press release.Quarterly revenue was $28.7 million compared with $0.1 million a year ago. The increase was attributed to revenue from a license agreement with Roche.